INSERM U1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Université Claude Bernard Lyon 1, 69434 Lyon, France.
The Lyon Hepatology Institute EVEREST, 69003 Lyon, France.
Int J Mol Sci. 2024 Jun 27;25(13):7073. doi: 10.3390/ijms25137073.
The development of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) has revolutionized the management of this pathology, as their use allows viral elimination in a large majority of patients. Nonetheless, HCV remains a major public health problem due to the multiple challenges associated with its diagnosis, treatment availability and development of a prophylactic vaccine. Moreover, HCV-cured patients still present an increased risk of developing hepatic complications such as hepatocellular carcinoma. In the present review, we aim to summarize the impact that HCV infection has on a wide variety of peripheral and intrahepatic cell populations, the alterations that remain following DAA treatment and the potential molecular mechanisms implicated in their long-term persistence. Finally, we consider how recent developments in single-cell multiomics could refine our understanding of this disease in each specific intrahepatic cell population and drive the field to explore new directions for the development of chemo-preventive strategies.
直接作用抗病毒药物(DAAs)的发展彻底改变了丙型肝炎病毒(HCV)的治疗方法,因为它们的使用使大多数患者能够消除病毒。然而,由于 HCV 的诊断、治疗方法的可及性和预防性疫苗的开发所面临的诸多挑战,HCV 仍然是一个主要的公共卫生问题。此外,HCV 治愈的患者仍然存在发生肝并发症(如肝细胞癌)的风险增加。在本次综述中,我们旨在总结 HCV 感染对多种外周和肝内细胞群体的影响、DAA 治疗后仍存在的改变,以及涉及它们长期持续存在的潜在分子机制。最后,我们考虑单细胞多组学的最新进展如何使我们更深入地了解每种特定肝内细胞群体中的这种疾病,并促使该领域探索开发化学预防策略的新方向。